Gilead Sciences Is Expanding Aggressively Beyond Traditional Oncology Gilead Sciences remains one of the strongest revenue generators in oncology cell […]
The biotechnology industry has moved far beyond traditional pharma. Today, it is a high-tech ecosystem powered by gene editing, mRNA
The pharmaceutical industry in 2025–2026 is increasingly being shaped by a “winner-takes-most” innovation cycle, where a small group of high-impact
Cell & Gene Therapy in 2026 is no longer an experimental corner of biotechnology.It is rapidly becoming a large-scale industrial